Skip to main content

Advertisement

SpringerLink
Log in

Barriers to achieving controlled rheumatoid arthritis in the United Arab Emirates: a cross-sectional study

  • Short Communication - Food for Thought
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

To better understand the factors that affect low disease activity (DAS28 ≤ 3.2, LDA) in rheumatoid arthritis (RA) and barriers within the UAE, demographic/treatment data and DAS28 scores were collected through chart reviews of 182 consecutive RA patients seen at a private clinic in Dubai over a 2-month period. Patients were separated into a LDA group and a group comprised of moderate (3.2 < DAS28 < 5.1) or high disease activity (DAS28 ≥ 5.1) (MHDA). We then examined variables that may be associated with LDA and re-examined the MHDA group for barriers. While 97 (53 %) of the 182 patients had achieved the treatment target of DAS28 ≤ 3.2, 85 (47 %) had MHDA. A significantly larger portion of LDA patients had been previously treated with sulfasalazine (36 in LDA vs. 14 in MHDA, P = 0.002) or was presently on biological treatments (24 vs. 9, P = 0.013). For the 85 MHDA patients, 40 (22 % of 182) exhibited resistant disease with 25 (13.7 % of 182) failing their current first tier disease-modifying anti-rheumatic drug (DMARD) treatment or combinations and 15 (8.2 % of 182) failing current anti-TNF or biologic treatment. Reasons listed were primarily socioeconomic with 40 % of the resistant disease group unable to afford biologicals and 52 % of the patient-driven preference group discontinuing DMARDs against professional advice. Going forward, emphasis on the agreement between patient and rheumatologist on treatment, specifically regarding how DMARDs help relieve symptoms and their proper use, could help reduce the percentage of MHDA patients in the UAE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G et al (2010) Treating rheumatoid arthritis to target recommendations of an international task force. Ann Rheum Dis 69:631–637

    Article  PubMed Central  PubMed  Google Scholar 

  2. Schoels M, Knevel R, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas DT et al (2010) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 69:638–643

    Article  PubMed Central  PubMed  Google Scholar 

  3. Knevel R, Schoels M, Huizinga TW, Aletaha D, Burmester GR, Combe B et al (2010) Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:987–994

    Article  CAS  PubMed  Google Scholar 

  4. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D et al (2010) DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 69:65–69

    Article  CAS  PubMed  Google Scholar 

  5. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D et al (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372:375–382

    Article  CAS  PubMed  Google Scholar 

  6. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37

    Article  CAS  PubMed  Google Scholar 

  7. Tymms K, Zochling J, Scott J, Bird P, Burnet S, de Jager J et al (2014) Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity. Arthritis Care Res 66:190–196

    Article  CAS  Google Scholar 

  8. Sokka T, Envalds M, Pincus T (2008) Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. Mod Rheumatol 18:228–239

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Emery P, Durez P, Dougados M, Legerton CW, Becker JC, Vratsanos G et al (2010) Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 69:510–516

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM et al (2008) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the Best study): a randomized, controlled trial. Arthritis Rheum 58(Suppl 2):126–135

    Google Scholar 

  11. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J et al (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63:573–586

    Article  PubMed Central  PubMed  Google Scholar 

  12. Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F et al (2009) Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 11:R7

    PubMed Central  PubMed  Google Scholar 

  13. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emergy P, Gaujoux-Viala C et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964–975

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Gaujoux-Viala C, Smolen JS, Landewé R, Dougados M, Kvien TK, Mola EM et al (2010) Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:1004–1009

    Article  CAS  PubMed  Google Scholar 

  15. Plosker GL, Croom KF (2005) Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 65:2591

    Article  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Nurse Joyce Raymond Daoud for her generous help with data collection.

Conflict of interest

The authors declare no conflict of interests.

Author information

Authors and Affiliations

  1. Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA

    Mira Noura Moufarrej

  2. Department of Public Health, Weill Cornell Medical School, Doha, Qatar

    Ziyad Mahfoud

  3. Dr. Humeira Badsha Medical Center Dubai, Dubai, UAE

    Humeira Badsha

Authors
  1. Mira Noura Moufarrej
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ziyad Mahfoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Humeira Badsha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mira Noura Moufarrej.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moufarrej, M.N., Mahfoud, Z. & Badsha, H. Barriers to achieving controlled rheumatoid arthritis in the United Arab Emirates: a cross-sectional study. Rheumatol Int 35, 759–763 (2015). https://doi.org/10.1007/s00296-014-3151-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-014-3151-7

Keywords

Search

Navigation